Icos Pafase for sepsis discontinued
Executive Summary
Icos discontinues severe sepsis agent Pafase after Phase III study failed to meet primary efficacy endpoint of 28-day all-cause mortality. Icos commenced COMPASS trial in April 2001; the study had enrolled 1,250 patients of 2,500 planned. Icos hoped to gain approval for Pafase (recombinant human platelet-activating factor acetylhydrolase) based on the single study (1"The Pink Sheet" Aug. 27, 2001, p. 25). Icos has a second compound, IC14, in Phase II for community acquired pneumonia-related sepsis...